WO2009106322A1 - Procédé d'enrichissement ou d'analyse de fragments d'adn d'un échantillon d'adn génomique complexe - Google Patents
Procédé d'enrichissement ou d'analyse de fragments d'adn d'un échantillon d'adn génomique complexe Download PDFInfo
- Publication number
- WO2009106322A1 WO2009106322A1 PCT/EP2009/001362 EP2009001362W WO2009106322A1 WO 2009106322 A1 WO2009106322 A1 WO 2009106322A1 EP 2009001362 W EP2009001362 W EP 2009001362W WO 2009106322 A1 WO2009106322 A1 WO 2009106322A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- genomic dna
- probes
- fragments
- carrier
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 76
- 239000012634 fragment Substances 0.000 title claims abstract description 44
- 238000004458 analytical method Methods 0.000 title abstract description 8
- 108020004414 DNA Proteins 0.000 claims description 110
- 102000053602 DNA Human genes 0.000 claims description 94
- 239000003298 DNA probe Substances 0.000 claims description 26
- 239000000523 sample Substances 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 230000035772 mutation Effects 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 238000012163 sequencing technique Methods 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 9
- 238000013467 fragmentation Methods 0.000 claims description 9
- 238000006062 fragmentation reaction Methods 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 7
- 108010090804 Streptavidin Proteins 0.000 claims description 6
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 claims description 4
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 238000004925 denaturation Methods 0.000 claims description 4
- 230000036425 denaturation Effects 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 238000002372 labelling Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000007767 bonding agent Substances 0.000 claims 1
- 230000003100 immobilizing effect Effects 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 239000002585 base Substances 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000002663 nebulization Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002313 adhesive film Substances 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 description 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000019476 oil-water mixture Nutrition 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
Definitions
- the present invention relates to a method for enriching contiguous genomic DNA fragments from complex genomic DNA to be examined, and to a method for analyzing the DNA fragments obtained by this enrichment method, and to the use of the method for studying mutations in genomic DNA, in particular mutations in genes associated with certain diseases and / or in the identification of genes associated with certain diseases.
- a major goal of molecular diagnostic science is namely to identify with the available methods and techniques by means of a specific enrichment within the complex structure of the genomic DNA sequence sections or genes about which diseases can be diagnosed and possibly also treated specifically.
- novel sequencing technologies high density parallel sequencing
- complete bacterial genomes 100 Mb
- de novo sequenced within three to five days at a time.
- human genome, as well as the genomes of many other species exceeds the sequencing capacity of these technologies many times over, because deviations from the normal state have to be investigated independently 5 to 20 times before, for example, a pathological mutation can be detected with sufficient certainty.
- the size of the mammalian genomes (up to 3 Gb) has the great disadvantage that careful screenings can not be performed with individual experiments.
- PCR approaches that are used as a basis for the mutation search must first be tested, which is very time-consuming and leads to a high personnel outlay. Performing the PCR reactions also requires a great deal of time and money, since these must be carried out using comparable protocols in order to achieve reproducible and meaningful results, so that on the one hand these reactions must first be established, and on the other hand often after the establishment the reactions are required for the analysis of an individual.
- mutation search in unknown disease genes today presents the science with great challenges.
- the positional cloning technique was used to identify disease genes, leading to relevant medical breakthroughs. Beginning with the coupling analysis in large families with the subsequent sequencing of candidate genes, recurring circumscribed sections of the human genome are analyzed.
- Candidate regions that is, regions where there is a likelihood of mutations that can cause disease, are usually around 500 kb to 10 Mb in size. Therefore, it would be desirable to develop a method by which to enrich and subsequently analyze DNA molecules of any patient of that particular candidate region.
- this object is achieved by a method comprising the following steps:
- step a) providing double-stranded DNA probes having sequences which correspond to sequences in the complex genomic DNA to be examined, b) immobilization of the double-stranded DNA probes from step a) to a carrier,
- the present invention provides an enrichment method of smaller DNA fragments of complex genomic DNA to be examined, which is highly flexible and which allows DNA fragments of interest to be rapidly and specifically enriched, after which they can subsequently be reliably analyzed, for example by means of a in vitro amplification or direct sequencing.
- the present invention provides a novel method of sample enrichment which can successfully and reproducibly reduce the complexity of genomic DNA.
- DNA probes are initially provided which are immobilized on a support, for example via specific markings.
- the DNA probes, or the source of the probes are thereby selected specifically with regard to the genome section to be examined, and a random fragment length of about 100 bp to 3000 bp, in particular of between 250 bp and 1000 bp, can be found to be advantageous to have.
- After immobilization of the probes they are denatured, ie the double strand of the DNA probes is broken up into two single strands.
- the genomic DNA to be examined is randomly fragmented, with fragments having a size of approximately 100 to 3000 bp, in particular from 250 to 1000 bp, having proven particularly advantageous.
- these details of the fragment lengths are merely exemplary, which is why smaller or larger lengths can be used.
- the genomic DNA is optionally denatured, ie broken down into single strands, this being done, for example, by heating the fragments in a buffer, preferably in a hybridization buffer, or else alkaline.
- a buffer preferably in a hybridization buffer, or else alkaline.
- denaturation is not always necessary since it is already present in single-stranded form. It will be apparent to those skilled in the art that, depending on the nature and form of the genomic DNA to be tested, it must or may not provide for a denaturation step.
- the fragmentation of the genomic DNA can be carried out, for example, by means of one or more restriction enzymes, by ultrasonic sonication, by nebulization.
- the fragmented and optionally denatured genomic DNA is then added to the immobilized on the support probe, for example.
- an amount of 0.1-20 micrograms wherein an amount of 10 to 20 micrograms has proved to be advantageous, after which the approach is incubated for hybridization over a period of time.
- two DNA single strands possessing complementary base sequences assemble into duplexes.
- the hybridization conditions between probe and target ie the fragments
- Conditions are regularly selected which are generally uniformly stable independently of the sequences specifically involved, with factors to be taken into account being the buffer, incubation time and incubation temperature.
- a hybridization buffer which contains 5 ⁇ SSC (0.75 M NaCl, 75 mM Na citrate, pH 7 0.1% (w / v) N-lauryl sarcosine, 0.02% (W / V) SDS, 2%.
- the reaction is then incubated, for example, for a period of 1 to 80 hours, preferably 60 hours.
- the support may be washed, for example, over one to several, preferably three, washes with a wash buffer, thereby removing any non-hybridization-bound portions of the target DNA.
- a wash buffer any washing buffer can be used which has no influence on the hybridized products, but with which unbound genomic DNA fragments can be washed off.
- the complementary to the single-stranded DNA probes bound, also single-stranded DNA fragments (the “targets” or targets) of the genomic DNA are mobilized, for example.
- alkaline lysis or by heat By “elution” is meant any method of action by which the targets are detached from the carrier - and thus from the probes immobilized on the carrier. It is understood that fragments obtained hereby may have to be neutralized in the solution for further analysis, in particular if alkaline lysis is used for the immobilization. It will be clear to the person skilled in the art which conditions he has to choose for which analysis in order to be able to carry them out. Thus, it is important in the method according to the invention that the double-stranded DNA probes have already been denatured and added to single-stranded DNA before addition of the target DNA.
- genomic DNA or “genome” is understood to mean the entire genetic material of an organism.
- the DNA (deoxyribonucleic acid) derived from the genetic material in the chromosome of a particular organism is the “genomic DNA”.
- a “genomic library” or “genomic library DNA” is a collection of clones made from a set of randomly generated, overlapping DNA fragments representing the entire genome of an organism. This genomic DNA, also referred to herein as “library DNA”, is often already present in single stranded form.
- genomic "DNA fragments” are to be understood here as meaning smaller sections of the total genome, which may have a length of about 50 to about 5000 bp, with the genome of, for example, mammals being up to 3 Gb in size can own.
- genomic DNA not only the entire genomic DNA of an organism derived or derived from the genetic material in the chromosome of a particular organism can be understood, but also those in the form of a library or library DNA fragments representing the entire genome of an organism.
- a genomic library For the preparation of a genomic library, the entire cellular DNA of an organism is broken down by restriction enzymes into fragments, which are then inserted and propagated in a suitable cloning vector, for example bacteriophages or cosmids. If only a part of all DNA regions found in the genome of an organism is contained in a gene library, it is called a subgenomic library.
- probe as used herein is meant an oligonucleotide capable of binding in a base-specific manner with a complementary strand of nucleic acid.
- oligonucleotide each nucleic acid
- the length of the oligonucleotides is usually at least 5, 10 or 20 bases long and can be up to 50, 100, 1000 or more bases long. Oligonucleotides may also include peptide nucleic acids or analogous nucleic acids.
- a “carrier” is to be understood as meaning any substrate to which nucleic acid probes can be attached.
- a plurality of different probes may be coupled to the surface of the carrier at various known locations.
- Such carriers are then also referred to as “chips” or “microarrays”.
- the surface of the carrier or the substrate can be produced in virtually any shape or in a plurality of surfaces, so that, for example, carriers in the form of (microtiter) plates, a sheet, of fibers or glass, etc. can be used, which is suitable for attaching probes.
- the genome or genomic DNA to be tested is not limited to humans as a source, but extends to include, but is not limited to, mammals, plants, bacteria or cells derived from any of the above. It goes without saying that it is also possible to resort to "library DNA" as starting material for genomic DNA.
- BAC clones bacterial artificial chromosome ", artificial bacterial chromosome
- the freely available BAC cloning collection 32k (Osoegawa et al., "A Bacterial Artificial Chromosomal Library for Sequencing the Complete Human Genome", Genome Research 2001; 11: 483-496) is useful in the 150,000 to 250,000 contiguous bases of the human genome are each contained in an artificial bacterial chromosome, which can be produced at any time highly pure by bacteria.
- fragmentation can be divided into smaller sections by means of one or more restriction enzymes, by ultrasound, by nebulization (compressed air or nitrogen).
- the probes in step b) are immobilized on the support via a marking.
- a marking means any chemical, biological or physical modification of the probes which make it possible to attach the probes to the support and thus immobilize it thereon.
- a marker is used for labeling the double-stranded DNA probes, which has a specific or unspecific affinity for the carrier.
- the probes bind to the carrier arbitrarily - via the marker - ie it does not depend on the nature of the surface of the carrier to which the probes are to be bound .
- the probes bind very specifically to the - possibly correspondingly processed - surface of the carrier and possibly to specific locations on the latter. It is preferred for a specific affinity of the marker if the marker is biotin-dUTP. This can then, in a preferred development of the method, be attached terminally to the probe, again being preferred if a terminal transferase is used for the label.
- Terminal transferase is an enzyme that mediates the template-independent attachment of deoxynucleotides (2'-deoxyribonucleoside monophosphates) to the terminal 3'-OH groups of DNA molecules. Therefore, this enzyme may, for example, attach biotin-dUTP to the DNA probes.
- the carrier has a coating with a specific affinity for the marker, wherein, when the marker is biotin-dUTP, it is preferred if the immobilization of the labeled double-stranded DNA probes in step c) via streptavidin takes place, with which the carrier is coated.
- Streptavidin a protein isolated from a bacterium, binds biotin to its four subunits. In general, however, any modification can be used which by high-affinity interactions between the partners of a specific binding pair, such. Biotin / streptavidin or avidin, hapten / anti-hapten antibody, sugar / lectin, etc., can be mediated.
- the method is furthermore generally preferred if the carrier is selected from the group consisting of microtiter plates, centrifugation columns, magnetic beads, paramagnetic beads. It will be understood that any substrate that can be modified and used for the purposes herein can serve as a carrier.
- the prior art discloses a multiplicity of carrier substrates which are suitable for the present method and which are well known to the person skilled in the art.
- step d) is carried out before or in parallel with one of the previous steps. It is understandably preferred to accelerate the process if the step of fragmenting and denaturing the genomic DNA is carried out in parallel to the fragmentation and optionally labeling and immobilization of the probes. This However, it also depends on the probes / genomic DNA material to be used, and it will be clear to the person skilled in the art which sequence should be used in each case.
- step c) and / or the genomic DNA in step d) by heat, alkali or acid and hydrogen bonding solvents, such as. As urea, formamide, is performed. It is understood that the skilled worker can also use denaturing agents in a mixture.
- the elution of the genomic DNA fragments is carried out by methods selected from the group consisting of heat exposure, acid or alkali treatment and the use of hydrogen bonding solvents, such as. As urea, formamide.
- the invention further relates to a method of analyzing genomic DNA characterized by the steps of enrichment by the method of the invention and analyzing the eluted genomic DNA fragments.
- the analysis is carried out by one or more of the methods selected from the group consisting of polymerase chain reaction, sequencing, in particular direct sequencing, and clonal amplification on glass surfaces.
- the PCR which amplifies specific DNA fragments in vitro, is a highly sensitive technique that allows one or more specific double-stranded DNA fragments to accumulate millions of times within a very short time, even from very small amounts of heterogeneous DNA.
- the so-called emPCR emulsion based PCR
- the microbeads are coupled to the single-stranded DNA fragments, with the amplification reagents in emulsified in an oil-water mixture (see, for example, Margulies et al., (2005) Nature; 437: 376-380).
- the genomic DNA obtained by enrichment can also be sequenced, for example, with so-called next-generation sequencing machines in which, instead of cloning into bacterial or viral systems for propagation of individual sequences, a direct clonal amplification of individual molecules takes place.
- the genomic DNA is provided after the fragmentation in a further step with PCR or Sequenzieradaptern (production of the so-called library).
- the recovered library DNA can then be amplified directly clonally (for example, microbead-coupled emPCR (Margulies et al. (2005) Nature; 437: 376-380) for the 454 method (see www.
- the method be used to study mutations in genomic DNA, wherein in one embodiment it is preferred that the method be used to study mutations in genes associated with certain diseases, and preferred in another embodiment when the method is used to identify genes associated with certain diseases.
- LRRK2 mutations in genes known to be associated with certain diseases or symptoms are investigated. For example, it has recently been shown that a single gene mutation is the cause of one of 25 Parkinson's cases worldwide. Leave the studies suggest that the mutation in a recently discovered gene called LRRK2 causes about five percent of inherited Parkinson's cases and about two percent of sporadic cases.
- hitherto unknown genes can be identified with the method according to the invention, which are associated with diseases.
- risk genes for Crohn's disease and type 2 diabetes have recently been identified.
- the methods of the present invention provide an excellent tool to improve such analyzes, both in terms of cost and time required, and in reliability and flexibility.
- FIG. 1 Genomic enrichment of human DNA sections complementary to chromosome 5-BAC (RPH 795P7).
- a fragmented and biotin-labeled BAC probe (RP11795P7, chromosome 5) was used, at a concentration of 150 ng / ⁇ l. Of these, 1.0 .mu.l, 0.5 .mu.l or 1.0 .mu.l of a 1:10 dilution were used. The average length of the fragments was about ⁇ 400 bp (base pairs). Fragmentation was performed by nebulizing the BAC DNA to 200 to 800 bp fragments. This was followed by purification of the fragments over a MinElute ® column (Qiagen, Hilden, Germany). The fragments were further labeled with biotin by a terminal transferase with biotin-16-ddUTP (each Roche Diagnostics, Mannheim, Germany).
- human genomic DNA was fragmented by nebulization to about 200 bp to 800 bp. These DNA fragments were purified by MinElute ® column and small fragments ( ⁇ 250 bp) by Ampure ® -Beads (® Agenco ⁇ rt Bioscien- ce, Beverly MA, USA) away. After elution of the DNA from the beads, the fragments were "end-poled” and phosphorylated by T4 DNA polymerase and T4 polynucleotide kinase (PNK) and dATP (New England Biolabs GmbH, Frankfurt, Germany), followed by further purification a MinElute ® column.
- PNK T4 polynucleotide kinase
- the fragments were used at a concentration c of 580 ng / ul to give 4.0 ul (equivalent to about 2 ug) 2.0 ul (corresponding to about 1 ug) and 1.0 ul (the length of the fragments averaged about 600 bp, pooled F # 17, and if the fragments were to be used for amplification after enrichment, for example, the "polis hed" DNA fragments specific adapter (single strand adapter or double strand adapter) ligated.
- streptavidin-coated microtiter plates were used by Thermo Scientific (Waltham, USA, catalog number 95 029 362).
- the biotin labeled BAC probe (150 ng, approximately 400 bp) was loaded with 50 ⁇ l binding buffer (10 mM Tris-HCl, 2M NaCl, ImM EDTA, 0.1% Tween 20, pH 7.6) into the wells of the streptavidin-coated ones Plate pipetted.
- the wells were then sealed with adhesive film and incubated for 1 hour at room temperature in the Platten thoroughlyelthermoblock at speed 2. Subsequently, the plate was briefly centrifuged and the buffer removed; This was followed by a washing step with 0.5 M NaOH and a 10-minute incubation with 100 ⁇ l 0.5M NaOH to denature the immobilized probes.
- hybridization buffer 5x SSC (0.75M NaCl, 75 mM NaCitrate, pH 7 0.1% (w / v) N-lauryl sarcosine, 0.02% (w / v) SDS, 2% Blocking Reagent ( 20 mg) and denatured for 5 minutes by boiling at 95 ° C.
- 100 ⁇ l of hybridization buffer preheated to hybridization temperature were initially introduced, and the denatured DNA was pipetted in, followed by closed the wells with adhesive film.
- the plate was incubated for about 60 hours at about 55 ° C on the thermoblock at speed 2 to achieve in the wells a temperature of about 50 0 C, at which the fragments hybridize to the probes.
- the plate was tightly closed to prevent dehydration. Subsequently, the plate was briefly centrifuged. The wells were washed with yes 300 .mu.l PBS + 0.05% Tween 20 (and the contents of the wells mixed carefully twice with the pipette); the buffer was then removed and allowed to dry on paper for the last wash cycle in reverse.
- the PCR detection was carried out using primers for the markers D5S818 (9791/9792) and D13S317 (9793/9794) in a multiplex reaction, the subsequent fragment analysis being carried out on the CEQ8000 (Beckman Coulter).
- the results are shown in FIG. It can be seen that the BAC clone (chromosome 5) used for the enrichment showed the D5S818 allele "13".
- the heterozygous human DNA used showed the D5S818 features "11” and "12” (Chromatogam D). All genomic enhancements were positive for the expected features "11” and "12” as well as for a more or less pronounced feature "13” (residues of BAC DNA in the eluate, Chromatogram AC).
- the method according to the invention it was possible to achieve a 10,000-fold enrichment of the specific DNA sections with separation of the unspecific DNA.
- a high enrichment efficiency offers the advantage that the enriched DNA can be used, for example, in an emulsion PCR (em-PCR) and in a subsequent GS-FLX sequencing.
- em-PCR emulsion PCR
- GS-FLX sequencing GS-FLX sequencing.
- in the method according to the invention can be dispensed with a PCR as an enrichment method, thereby avoiding the often occurring in a PCR uncontrolled base changes, which would lead to a falsified result.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne un procédé d'enrichissement de petits fragments d'ADN d'un ADN génomique complexe, ainsi qu'un procédé d'analyse d'ADN génomique, le procédé étant utilisé pour l'enrichissement.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008013715.4 | 2008-02-29 | ||
DE200810013715 DE102008013715B4 (de) | 2008-02-29 | 2008-02-29 | Verfahren zur DNA-Analyse |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009106322A1 true WO2009106322A1 (fr) | 2009-09-03 |
Family
ID=40612940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/001362 WO2009106322A1 (fr) | 2008-02-29 | 2009-02-26 | Procédé d'enrichissement ou d'analyse de fragments d'adn d'un échantillon d'adn génomique complexe |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE102008013715B4 (fr) |
WO (1) | WO2009106322A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2913660A4 (fr) * | 2012-10-25 | 2016-06-29 | Olympus Corp | Méthode de détection de particules cibles |
US9488578B2 (en) | 2011-08-26 | 2016-11-08 | Olympus Corporation | Single particle detection device, single particle detection method, and computer program for single particle detection, using optical analysis |
US9575060B2 (en) | 2012-04-18 | 2017-02-21 | Olympus Corporation | Method for detecting a target particle |
US10481158B2 (en) | 2015-06-01 | 2019-11-19 | California Institute Of Technology | Compositions and methods for screening T cells with antigens for specific populations |
US12258613B2 (en) | 2017-03-08 | 2025-03-25 | California Institute Of Technology | Pairing antigen specificity of a T cell with T cell receptor sequences |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0487104A1 (fr) * | 1990-11-22 | 1992-05-27 | Sumitomo Electric Industries, Ltd | Méthode pour immobiliser sur un support de l'ADN simple-brin faisant réagir uniquement sa partie terminale |
EP1184466A2 (fr) * | 2000-08-26 | 2002-03-06 | Affymetrix, Inc. | Enrichissiment et amplification des cibles d'acide nucleique pour l'analyse dans un réseau |
EP1630237A2 (fr) * | 2004-08-26 | 2006-03-01 | Agilent Technologies, Inc. | Isolement d'acides nucléiques par hybridation avec une phase solide |
US20070141604A1 (en) * | 2005-11-15 | 2007-06-21 | Gormley Niall A | Method of target enrichment |
-
2008
- 2008-02-29 DE DE200810013715 patent/DE102008013715B4/de not_active Expired - Fee Related
-
2009
- 2009-02-26 WO PCT/EP2009/001362 patent/WO2009106322A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0487104A1 (fr) * | 1990-11-22 | 1992-05-27 | Sumitomo Electric Industries, Ltd | Méthode pour immobiliser sur un support de l'ADN simple-brin faisant réagir uniquement sa partie terminale |
EP1184466A2 (fr) * | 2000-08-26 | 2002-03-06 | Affymetrix, Inc. | Enrichissiment et amplification des cibles d'acide nucleique pour l'analyse dans un réseau |
EP1630237A2 (fr) * | 2004-08-26 | 2006-03-01 | Agilent Technologies, Inc. | Isolement d'acides nucléiques par hybridation avec une phase solide |
US20070141604A1 (en) * | 2005-11-15 | 2007-06-21 | Gormley Niall A | Method of target enrichment |
Non-Patent Citations (4)
Title |
---|
ALBERT THOMAS J ET AL: "Direct selection of human genomic loci by microarray hybridization", NATURE METHODS, NATURE PUBLISHING GROUP, GB, vol. 4, no. 11, 1 November 2007 (2007-11-01), pages 903 - 905, XP002499757, ISSN: 1548-7091, [retrieved on 20071014] * |
BASHIARDES STAVROS ET AL: "Direct genomic selection", NATURE METHODS JAN 2005,, vol. 2, no. 1, 1 January 2005 (2005-01-01), pages 63 - 69, XP002525087 * |
LOVETT ET AL: "Fishing for complements: finding genes by direct selection", TRENDS IN GENETICS, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 10, no. 10, 1 October 1994 (1994-10-01), pages 352 - 357, XP023477939, ISSN: 0168-9525, [retrieved on 19941001] * |
OKOU DAVID T ET AL: "Microarray-based genomic selection for high-throughput resequencing", NATURE METHODS NOV 2007,, vol. 4, no. 11, 1 November 2007 (2007-11-01), pages 907 - 909, XP002524506 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9488578B2 (en) | 2011-08-26 | 2016-11-08 | Olympus Corporation | Single particle detection device, single particle detection method, and computer program for single particle detection, using optical analysis |
US9575060B2 (en) | 2012-04-18 | 2017-02-21 | Olympus Corporation | Method for detecting a target particle |
EP2913660A4 (fr) * | 2012-10-25 | 2016-06-29 | Olympus Corp | Méthode de détection de particules cibles |
US10481158B2 (en) | 2015-06-01 | 2019-11-19 | California Institute Of Technology | Compositions and methods for screening T cells with antigens for specific populations |
US12258613B2 (en) | 2017-03-08 | 2025-03-25 | California Institute Of Technology | Pairing antigen specificity of a T cell with T cell receptor sequences |
Also Published As
Publication number | Publication date |
---|---|
DE102008013715A1 (de) | 2010-04-08 |
DE102008013715B4 (de) | 2011-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69433136T2 (de) | Nukleinsäure-isolierung | |
DE69825240T2 (de) | Verfahren zur subtraktiven hybridisierung und differenziellen analyse | |
US6156502A (en) | Arbitrary sequence oligonucleotide fingerprinting | |
US20120045771A1 (en) | Method for analysis of nucleic acid populations | |
DE69711895T2 (de) | Characterisierung von dna | |
DE112010004821T5 (de) | Prozessierung amplifizierter DNA-Fragmente zur Sequenzierung | |
US20070148690A1 (en) | Analysis of gene expression profiles using sequential hybridization | |
DE112013004650T5 (de) | Multiplexpyrosequenzierung unter Verwendung nichtinterferierender, rauschbeendender Polynukleotididentifikationstags | |
DE102008013715B4 (de) | Verfahren zur DNA-Analyse | |
DE10149947A1 (de) | Mikrofluidisches Extraktionsverfahren | |
DE102005034628B4 (de) | Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA | |
EP1366195A2 (fr) | Procede de detection de molecules d'acide nucleique | |
KR20240085399A (ko) | Dna 단편의 멀티 결합 조립 반응을 이용한 단일세포의 다중체 전장 시퀀싱 분석방법 | |
DE102019118332B4 (de) | Verfahren und testkit zur bisulfitmodifizierung von dna | |
EP0698122B1 (fr) | Agent de diagnostic complexe de l'expression genetique et son procede d'application en diagnostic medical et pour isoler des genes | |
EP1816217B1 (fr) | Méthode pour la détection d'une pluralité d'acides nucléiques cibles | |
US20100204050A1 (en) | Target preparation for parallel sequencing of complex genomes | |
EP1537246B1 (fr) | Procédé d'amplification d'informations génétiques utilisant des oligonucléotides se liant aux sites multiples dans le génome | |
US20210198807A1 (en) | Methods and systems for production of dna libraries directly from a stool sample for 16s metagenomics next generation sequencing | |
DE10240746A1 (de) | Verfahren zum Nachweis von Nukleinsäuresequenzen mittels spaltbarer Sondenmoleküle | |
EP2471955B1 (fr) | Molécule d'acide nucléique hybridisable spécifique à l'organisme | |
EP2706124B1 (fr) | Mise en évidence simultanée de différentes micro-formes de biogenèse RNA | |
DE19821114A1 (de) | Methode zur Identifizierung und Darstellung interindividueller DNA-Sequenzunterschiede | |
RU2585519C2 (ru) | Способ селективного отбора целевых участков днк | |
EP1650314A1 (fr) | Détermination dynamique d'analytes en utilisant une puce localisée sur une surface interne |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09713694 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09713694 Country of ref document: EP Kind code of ref document: A1 |